Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01AG058724 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. These changes include a buildup of two proteins within the brain, called amyloid and tau. The two goals of this study are
(1) to determine whether patients with mild cognitive impairment or dementia-Alzheimer's type (DAT) are able to demonstrate decisional capacity to engage in PET amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to PET amyloid and tau biomarker disclosure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Disclosure | Experimental | Participants who demonstrated decisional capacity for and interest in disclosure (or whose care partner is able to do so) will receive the participant's personalized PET amyloid and tau biomarker status, as well as information about the meaning and clinical utility of this information and recommendations for next steps (e.g., discussing findings with his/her provider). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PET Biomarker Disclosure | Behavioral | Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested. |
| Measure | Description | Time Frame |
|---|---|---|
| Participant Interest in PET Biomarker Disclosure | Percent of participants surveyed who were interested in receiving their PET biomarker feedback following education, prior to disclosure | Immediately Following Pre-Disclosure Education Session (within one month of enrollment) |
| Percent of Individuals Demonstrating Disclosure Decision-making Capacity | This interactive interview involves an assessment of understanding, appreciation, rationale, and communication of a decision regarding participating or not participating in PET biomarker disclosure. During an education session in which information about PET disclosure is reviewed, participants are asked questions to determine how well they comprehend and appreciated risks and benefits of engaging in PET biomarker disclosure. They are provided with prompts/clarification as needed. Examiners subjectively score each response as correct or incorrect and utilize this information to determine whether participants are demonstrate decisional capacity for PET biomarker disclosure. Results are pass (disclosure decisional capacity intact) or fail (disclosure decisional capacity not intact). Therefore, we will measure the percent of individuals who are able to pass this measure. | Immediately Following Pre-Disclosure Education Session (within one month of enrollment) |
| Effect of Disclosure (Time) and Biomarker Status on Positive and Negative Affect Scale - Short Form (PANAS-SF) Positive Subscale Score | This 10-item subscale asks respondents to rate the extent to which they are experiencing positive (e.g., excited, inspired) emotions on a Likert-style scale ranging from '1 = Very Slightly or Not at All' to '5=Extremely.' Scores range from 10-50, with higher scores indicating higher positive emotions. | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
| Effect of Disclosure (Time) and Biomarker Status on Positive and Negative Affect Scale - Short Form (PANAS-SF) Negative Subscale Score |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ben Hampstead, PhD | University of Michigan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan Medical School, Department of Psychiatry | Ann Arbor | Michigan | 48105 | United States |
Individual participant data will not be shared with researchers outside of this study.
Not provided
Not provided
Not provided
Not provided
Not provided
161 total individuals were recruited for the study; however, 9 screen failed during the screening and consenting process and were not eligible to begin study activities
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Amyloid Positive Participants | Participants with amyloid positivity (amyloid positive, tau positive and amyloid positive, tau negative). |
| FG001 | Amyloid Negative Participants | Participants with negative amyloid results (amyloid negative, tau negative and amyloid negative, tau unknown; no participants had amyloid negative, tau positive results) |
| FG002 | Study Partners of Amyloid Positive Participants | Study partners of participants later found to have amyloid positivity |
| FG003 | Study Partners of Amyloid Negative Participants | Study partners of participants later found to be amyloid negative |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Education Session |
| |||||||||||||
| Disclosure Sesions |
|
152 total individuals were eligible and enrolled in the study; they are characterized below. Of these, 2 dyads (2 participants and 2 study partners) did not enter the Education Session intervention (1 dyad lost to follow-up before session, 1 dyad declined after further consideration). Therefore, 148 total individuals began and completed the Education Session.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Amyloid Positive Participants | Participants with amyloid positivity (amyloid positive, tau positive and amyloid positive, tau negative). |
| BG001 | Amyloid Negative Participants |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Missing age data for 1 study partner |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participant Interest in PET Biomarker Disclosure | Percent of participants surveyed who were interested in receiving their PET biomarker feedback following education, prior to disclosure | Only participants were surveyed on their interest in learning biomarker results. At the time of this outcome measure, neither participants nor study team knew the participants' amyloid status; therefore, this outcome was designed to be measured independent of biomarker status. | Posted | Count of Participants | Participants | Immediately Following Pre-Disclosure Education Session (within one month of enrollment) |
|
From enrollment until the end of follow-up, up to 9 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Amyloid Positive Participants | Participants with amyloid positivity (amyloid positive, tau positive and amyloid positive, tau negative). |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Annalise Rahman-Filipiak | University of Michigan | 7349363180 | rahmanam@umich.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 23, 2025 | Nov 5, 2025 | Prot_SAP_004.pdf |
| ICF | No | No | Yes | Informed Consent Form: Participant Consent - Education | Sep 8, 2022 | Jan 11, 2023 | ICF_000.pdf |
| ICF | No | No | Yes | Informed Consent Form: Participant Consent - Disclosure | Sep 8, 2022 | Jan 11, 2023 | ICF_001.pdf |
| ICF | No | No | Yes | Informed Consent Form: Co-Participant Consent - Education | Sep 8, 2022 | Jan 11, 2023 | ICF_002.pdf |
| ICF | No | No | Yes | Informed Consent Form: Co-Participant Consent - Disclosure | Sep 8, 2022 | Jan 11, 2023 | ICF_003.pdf |
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D001927 | Brain Diseases |
Not provided
Not provided
Participants and care partners who demonstrate intact decisional capacity to engage in PET biomarker disclosure, and who wish to receive the participant's PET results will be provided with education, results, and recommendations for next steps and supportive resources (the intervention). After this intervention, participants will complete follow-up evaluations of mood and anxiety within one week and at six weeks post disclosure.
Not provided
Not provided
Not provided
Not provided
|
This 10-item subscale asks respondents to rate the extent to which they are experiencing positive negative (e.g., distressed, ashamed) emotions on a Likert-style scale ranging from '1 = Very Slightly or Not at All' to '5=Extremely.' The scores range from 10-50, with higher scores indicating higher negative emotions. |
| Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
| Effect of Biomarker Status on Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Distress Score | Measures negative reactions to AD-related personal neuroimaging results received as part of disclosure (0-55; higher scores indicate higher distress) starting from immediately following disclosure to six weeks post-disclosure. | Immediately following disclosure (within 6 months of baseline) to 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
| Effect of Biomarker Status on Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Positive Emotions Score | Measures change in positive reactions to AD-related personal neuroimaging results received as part of disclosure (0-20; higher scores indicate higher positive emotions) starting from immediately following disclosure to six weeks post-disclosure. | Immediately following disclosure (within 6 months of baseline) to 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
| Effect of Disclosure (Time) and Biomarker Status on Stigma Scale for Chronic Illness (SSCI-8) Total Score | The Stigma Scale for Chronic Illness (SSCI-8) measures perceived and experienced stigma based on a chronic illness (in this case, cognitive disorder). The SSCI-8 demonstrates strong reliability for the measurement of both internalized (perceived) and enacted (experienced) stigma perceived by individuals with chronic neurological conditions. Respondents complete 8 items about experiences of stigma, rated on a Likert-style scale from 1 = 'Never' to 5 = 'Always'. Items are summed to a total score (min=8, max=40) with higher scores suggesting more stigma. | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
| Effect of Disclosure (Time) and Biomarker Status on Self-Efficacy for Managing Chronic Disease Scale (SECD) Total Score | The Self-Efficacy for Managing Chronic Disease (SECD) scale is a 6-item scale that measures perceived ability to self-manage the physical, emotional, and cognitive symptoms associated with their chronic disease. Items are listed on a 10-point scale ranging from 1 = 'Not at all confident' to 10 = 'Totally confident'. Item scores are summed and averaged. Lower scores suggest lower confidence in managing symptoms. Higher scores suggest higher confidence in managing symptoms. There are no clinical cut-offs for this measure. | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
| Effect of Disclosure (Time) and Biomarker Status on Future Time Perspectives Scale (FTP) Average Score | The Future Time Perspective (FTP) scale is a 10-item scale that measures the extent to which respondents feel that they have potential for productive and functional years ahead of them. Statements regarding positive and negative future time perspective are rated on a 7-point Likert-style scale, ranging from 1= 'Very untrue' to 7='Very true.' 3 items are reverse scored, then all items are summed and averaged. Minimum average score is 1, maximum average score is 7. Higher scores suggest greater time perspective. | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
| Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: Immediately Following Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | Immediately following disclosure (within 6 months of baseline) |
| Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: 1-Week Post-Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | 1-week post-disclosure (within 6.5 months of baseline) |
| Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: 6-Week Post-Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | 6 weeks post-disclosure (within 8 months of baseline) |
| Preparedness for Caregiving Scale (PCS) | This 8-item measure assesses the degree to which care partners of persons with cognitive impairment (e.g., MCI, DAT) perceive they are prepared for and able to manage various domains of caregiving such as providing physical care and emotional support, setting up in-home support services, and coping with stress due to caregiving. Items use a 5-point likert scale ranging from 0 = 'Not at all prepared' to 4 'Very well prepared'. An average score is generated (min=0, max=4) with higher scores indicating greater preparedness. | Measured at baseline, immediately post-disclosure (within 6 months of baseline), and at 1- (within 6.5 months of baseline) and 6-weeks post-disclosure (within 8 months of baseline) |
| Revised Scale for Caregiving Self-Efficacy | The Revised Scale for Caregiving Self-Efficacy is a 15-item scale consisting of 3 sub-scales, each containing 5-items, designed to measure perceived ability to manage aspects related to caregiving among caregivers of persons with dementia. Only one subscale was administered in this study: this 5-item subscale is used to measure the co-participant's perceived ability to manage the emotional stresses associated with caregiving. This measure will be administered to study partners only. Items are averaged (min=0, max=100) with higher scores indicating greater perceived confidence to manage the emotional stressed of caregiving. | Measured at baseline, immediately post-disclosure (within 6 months of baseline), and at 1- (within 6.5 months of baseline) and 6-weeks post-disclosure (within 8 months of baseline) |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Participants with negative amyloid results (amyloid negative, tau negative and amyloid negative, tau unknown; no participants had amyloid negative, tau positive results)
| BG002 | Study Partners of Amyloid Positive Participants | Study partners of participants later found to be amyloid positive |
| BG003 | Study Partners of Amyloid Negative Participants | Study partners of participants later found to be amyloid negative |
| BG004 | Total | Total of all reporting groups |
| Mean |
| Standard Deviation |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Education | Education data were missing for 1 participant and 3 study partners | Mean | Standard Deviation | years |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Percent of Individuals Demonstrating Disclosure Decision-making Capacity | This interactive interview involves an assessment of understanding, appreciation, rationale, and communication of a decision regarding participating or not participating in PET biomarker disclosure. During an education session in which information about PET disclosure is reviewed, participants are asked questions to determine how well they comprehend and appreciated risks and benefits of engaging in PET biomarker disclosure. They are provided with prompts/clarification as needed. Examiners subjectively score each response as correct or incorrect and utilize this information to determine whether participants are demonstrate decisional capacity for PET biomarker disclosure. Results are pass (disclosure decisional capacity intact) or fail (disclosure decisional capacity not intact). Therefore, we will measure the percent of individuals who are able to pass this measure. | Decision-making capacity was only measured in participants (not study partners) for the purpose of this aim. The aim also investigated differences in decision-making capacity for biomarker disclosure based on diagnosis (MCI vs. Dementia). At the time that this outcome was assessed, neither participants nor study team knew the participants' biomarker status. Therefore, decision-making capacity was compared only by participant diagnostic group. | Posted | Count of Participants | Participants | Immediately Following Pre-Disclosure Education Session (within one month of enrollment) |
|
|
|
|
| Primary | Effect of Disclosure (Time) and Biomarker Status on Positive and Negative Affect Scale - Short Form (PANAS-SF) Positive Subscale Score | This 10-item subscale asks respondents to rate the extent to which they are experiencing positive (e.g., excited, inspired) emotions on a Likert-style scale ranging from '1 = Very Slightly or Not at All' to '5=Extremely.' Scores range from 10-50, with higher scores indicating higher positive emotions. | Posted | Mean | Standard Deviation | PANAS Positive subscale score | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| Primary | Effect of Disclosure (Time) and Biomarker Status on Positive and Negative Affect Scale - Short Form (PANAS-SF) Negative Subscale Score | This 10-item subscale asks respondents to rate the extent to which they are experiencing positive negative (e.g., distressed, ashamed) emotions on a Likert-style scale ranging from '1 = Very Slightly or Not at All' to '5=Extremely.' The scores range from 10-50, with higher scores indicating higher negative emotions. | Posted | Mean | Standard Deviation | PANAS Negative Subscale Score | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
|
|
|
|
| Primary | Effect of Biomarker Status on Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Distress Score | Measures negative reactions to AD-related personal neuroimaging results received as part of disclosure (0-55; higher scores indicate higher distress) starting from immediately following disclosure to six weeks post-disclosure. | Posted | Mean | Standard Deviation | INI-AD Distress Subscale Total Score | Immediately following disclosure (within 6 months of baseline) to 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| Primary | Effect of Biomarker Status on Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Positive Emotions Score | Measures change in positive reactions to AD-related personal neuroimaging results received as part of disclosure (0-20; higher scores indicate higher positive emotions) starting from immediately following disclosure to six weeks post-disclosure. | Posted | Mean | Standard Deviation | INI-AD Positive Subscale Total Score | Immediately following disclosure (within 6 months of baseline) to 1-week post-disclosure (within 6.5 months of baseline), and 6-weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| Primary | Effect of Disclosure (Time) and Biomarker Status on Stigma Scale for Chronic Illness (SSCI-8) Total Score | The Stigma Scale for Chronic Illness (SSCI-8) measures perceived and experienced stigma based on a chronic illness (in this case, cognitive disorder). The SSCI-8 demonstrates strong reliability for the measurement of both internalized (perceived) and enacted (experienced) stigma perceived by individuals with chronic neurological conditions. Respondents complete 8 items about experiences of stigma, rated on a Likert-style scale from 1 = 'Never' to 5 = 'Always'. Items are summed to a total score (min=8, max=40) with higher scores suggesting more stigma. | Posted | Mean | Standard Deviation | SSCI-8 Total Score | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
|
|
|
|
| Primary | Effect of Disclosure (Time) and Biomarker Status on Self-Efficacy for Managing Chronic Disease Scale (SECD) Total Score | The Self-Efficacy for Managing Chronic Disease (SECD) scale is a 6-item scale that measures perceived ability to self-manage the physical, emotional, and cognitive symptoms associated with their chronic disease. Items are listed on a 10-point scale ranging from 1 = 'Not at all confident' to 10 = 'Totally confident'. Item scores are summed and averaged. Lower scores suggest lower confidence in managing symptoms. Higher scores suggest higher confidence in managing symptoms. There are no clinical cut-offs for this measure. | Posted | Mean | Standard Deviation | SECD Total Score | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
|
|
|
|
| Primary | Effect of Disclosure (Time) and Biomarker Status on Future Time Perspectives Scale (FTP) Average Score | The Future Time Perspective (FTP) scale is a 10-item scale that measures the extent to which respondents feel that they have potential for productive and functional years ahead of them. Statements regarding positive and negative future time perspective are rated on a 7-point Likert-style scale, ranging from 1= 'Very untrue' to 7='Very true.' 3 items are reverse scored, then all items are summed and averaged. Minimum average score is 1, maximum average score is 7. Higher scores suggest greater time perspective. | Posted | Mean | Standard Deviation | FTP Total Score | Change from Baseline to Immediately following disclosure (within 6 months of baseline), 1-week post-disclosure, and 6-weeks post-disclosure |
|
|
|
|
| Primary | Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: Immediately Following Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | Posted | Mean | Standard Deviation | % correct on comprehension measure | Immediately following disclosure (within 6 months of baseline) |
|
|
|
|
| Primary | Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: 1-Week Post-Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | Posted | Mean | Standard Deviation | Percent Correct | 1-week post-disclosure (within 6.5 months of baseline) |
|
|
|
|
| Primary | Effect of Diagnosis on Participant Comprehension/Recall of Results Percent Correct Score: 6-Week Post-Disclosure | This tool, created for the purpose of this study, measures participant's ability to understand their biomarker results and their meaning. Scores on the nine items are converted into a percent correct score, with higher scores indicating better comprehension and memory of results. | Posted | Mean | Standard Deviation | Percent Correct | 6 weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| Primary | Preparedness for Caregiving Scale (PCS) | This 8-item measure assesses the degree to which care partners of persons with cognitive impairment (e.g., MCI, DAT) perceive they are prepared for and able to manage various domains of caregiving such as providing physical care and emotional support, setting up in-home support services, and coping with stress due to caregiving. Items use a 5-point likert scale ranging from 0 = 'Not at all prepared' to 4 'Very well prepared'. An average score is generated (min=0, max=4) with higher scores indicating greater preparedness. | Posted | Mean | Standard Deviation | PCS total score | Measured at baseline, immediately post-disclosure (within 6 months of baseline), and at 1- (within 6.5 months of baseline) and 6-weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| Primary | Revised Scale for Caregiving Self-Efficacy | The Revised Scale for Caregiving Self-Efficacy is a 15-item scale consisting of 3 sub-scales, each containing 5-items, designed to measure perceived ability to manage aspects related to caregiving among caregivers of persons with dementia. Only one subscale was administered in this study: this 5-item subscale is used to measure the co-participant's perceived ability to manage the emotional stresses associated with caregiving. This measure will be administered to study partners only. Items are averaged (min=0, max=100) with higher scores indicating greater perceived confidence to manage the emotional stressed of caregiving. | Posted | Mean | Standard Deviation | total subscale score | Measured at baseline, immediately post-disclosure (within 6 months of baseline), and at 1- (within 6.5 months of baseline) and 6-weeks post-disclosure (within 8 months of baseline) |
|
|
|
|
| 0 |
| 60 |
| 0 |
| 60 |
| 0 |
| 60 |
| EG001 | Amyloid Negative Participants | Participants with negative amyloid results (amyloid negative, tau negative and amyloid negative, tau unknown; no participants had amyloid negative, tau positive results) | 0 | 18 | 0 | 18 | 0 | 18 |
| EG002 | Study Partners of Amyloid Positive Participants | Study partners of amyloid positive participants | 0 | 59 | 0 | 59 | 0 | 59 |
| EG003 | Study Partners of Amyloid Negative Participants | Study partners of amyloid negative participants | 0 | 11 | 0 | 11 | 0 | 11 |
Not provided
Not provided
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Immediate Post-Disclosure |
|
| 1-Week Post-Disclosure |
|
| 6-Week Post-Disclosure |
|
Evaluated the effect of disclosure (Time) x participant Amyloid Status on PANAS Positive subscale scores among study partners |
| .499 |
| Superiority |
| Immediately Post-Disclosure |
|
| 1-Week Post-Disclosure |
|
| 6-Week Post-Disclosure |
|
Evaluated the effect of disclosure (time) x participant amyloid status on study partners' PANAS negative subscale scores |
| .476 |
| Superiority |
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|
Examined the between-subjects effect of participant amyloid status on study partner INI-AD Distress subscale score
| <.001 |
| Superiority |
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|
Evaluated the effect of participant amyloid status on study partner INI-AD Positive Emotions subscale scores
| <.001 |
| Superiority |
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|
| 1-Week Post-Disclosure |
|
| 6-Week Post-Disclosure |
|
| Immediately Post-Disclosure |
|
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|
Evaluated the effect of disclosure (time) x participant amyloid status on study partners' FTP subscale scores
| .956 |
| Superiority |
| Superiority |
| Superiority |
| Superiority |
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|
| 1-Week Post-Disclosure |
|
| 6-Weeks Post-Disclosure |
|